325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC)

ESMO Real World Data and Digital Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles